Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.
To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Thromboxane b2
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Murphy NP et al. | Functional relevance of the expression of ligand-induced binding sites in the response to platelet GP IIb/IIIa antagonists in vivo. | 1998 | J. Pharmacol. Exp. Ther. | pmid:9694954 |
Levy M et al. | Cerebrospinal fluid prostaglandins after systemic dipyrone intake. | 1998 | Clin. Pharmacol. Ther. | pmid:9695726 |
Fagugli RM et al. | Reduction of renal functional reserve in kidney transplant recipients: a possible role of arachidonic acid metabolism alterations. | 1998 | Clin. Nephrol. | pmid:9696430 |
Iida T et al. | The effects of a thromboxane A2 synthesis inhibitor and a prostaglandin I2 analogue on experimental acute necrotizing pancreatitis in rats. | 1998 | Pancreas | pmid:9700944 |
Ingster LM and Feinleib M | Salicylate intake and cardiovascular disease: Ingster and Feinleib respond to Hu and Willett. | 1998 | Am J Public Health | pmid:9702172 |
Hsiao G et al. | Antiplatelet action of 3',4'-diisovalerylkhellactone diester purified from Peucedanum japonicum Thunb. | 1998 | Biol. Pharm. Bull. | pmid:9703250 |
Durando MM et al. | Endotoxin activation of mitogen-activated protein kinase in THP-1 cells; diminished activation following endotoxin desensitization. | 1998 | J. Leukoc. Biol. | pmid:9715266 |
Saareks V et al. | Nicotine stereoisomers and cotinine stimulate prostaglandin E2 but inhibit thromboxane B2 and leukotriene E4 synthesis in whole blood. | 1998 | Eur. J. Pharmacol. | pmid:9721044 |
Takami M and Tsukada W | Correlative alteration of thromboxane A2 with antigen-induced bronchoconstriction and the role of platelets as a source of TXA2 synthesis in guinea pigs: effect of DP-1904, an inhibitor of thromboxane synthetase. | 1998 | Pharmacol. Res. | pmid:9721601 |
Takami M and Tsukada W | In vitro effect of DP-1904, a novel anti-asthma agent, against antigen-induced constriction and TXB2 release from the isolated guinea-pig lung parenchymal tissue. | 1998 | Pharmacol. Res. | pmid:9721602 |